stockmarketproxy
/
RPRXNasdaq SEC EDGAR

Royalty Pharma plc

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 1802768
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$2.4B$2.3B$2.4B$2.2B$2.3B
Gross Profit——————
Operating Income$1.6B$1.3B$1.5B$307.1M$1.4B
Net Income$770.9M$859.0M$1.1B$42.8M$619.7M
Operating CF$2.5B$2.8B$3.0B$2.1B$2.0B
Capex——————
Free Cash Flow——————
Buybacks$1.2B$229.7M$304.8M—$0
Dividends——————
Gross Margin——————
Operating Margin65.6%57.1%63.4%13.7%62.5%
Net Margin32.4%37.9%48.2%1.9%27.1%
FCF Margin——————
R&D / Revenue19.0%0.1%2.2%7.9%8.7%
Effective Tax0.0%0.0%0.0%0.0%0.0%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
RPRX
4:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
RPRX
$1M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
RPRX
32.4%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%